

SECOND TRADEMARK PTO FORM-1449 INFORMATION DISCLOSURE CITATION		Inventor: KAUTZ	Art Unit: XX	
		Appl. No.: 10/590,803	Examiner: XX	
		Filing Date: August 25, 2006	Confirm. No.: XX	
U. S. PATENT DOCUMENTS				
Exam. Initial	Document No.	Issue/Public. Date	Inventor	
FOREIGN PATENT DOCUMENTS				
Exam. Initial	Document No.	Public. Date	Country	Translation
OTHER				
Exam. Initial	(Including Author, Title, Date, Pertinent Pages, etc.)			
	A34	Souness, J.E., "Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors", <u>Immunopharmacology</u> , Vol. 47, Pg. 127-162, (2000).		
	A35	Dyke, H.J., et al., "Update on the therapeutic potential of PDE4 inhibitors", <u>Expert Opin. Investig. Drugs</u> , Vol. 11, No. 1, Pg. 1-13, (2002).		
	A36	Montana, J.G., et al., "Chapter 5. Phosphodiesterase 4 Inhibitors", <u>Annual Reports in Medicinal Chemistry</u> , Vol. 36, Pg. 41-56, (2001).		
	A37	Schmidt, B.M.W., et al., "The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis", <u>J Allergy Clin Immunol</u> , Vol. 108, Pg. 530-536, 2001).		
Examiner <i>/Marcos Sznaidman/</i>			Date Considered 04/05/2011	

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP' 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /M.S./